Patent: 8,217,147

Summary for Patent: 8,217,147

Title:	Identification and engineering of antibodies with variant Fc regions and methods of using same
Abstract:	The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc.gamma.RIIIA and/or Fc.gamma.RIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by Fc.gamma.R is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.
Inventor(s):	Stavenhagen; Jeffrey (Brookville, MD), Gorlatov; Sergey (Gaithersburg, MD), Rankin; Christopher (Clarksburg, MD), Tuaillon; Nadine (Gaithersburg, PA)
Assignee:	MacroGenics, Inc. (Rockville, MD)
Application Number:	11/502,820
Patent Claims:	see list of patent claims

Details for Patent 8,217,147

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2025-08-10
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2025-08-10
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2025-08-10